Analysts See $-0.01 EPS for ChromaDex Corporation (CDXC)

February 15, 2018 - By Kurt Siggers

 Analysts See $ 0.01 EPS for ChromaDex Corporation (CDXC)

Analysts expect ChromaDex Corporation (NASDAQ:CDXC) to report $-0.01 EPS on March, 15.They anticipate $0.05 EPS change or 83.33 % from last quarter’s $-0.06 EPS. After having $-0.07 EPS previously, ChromaDex Corporation’s analysts see -85.71 % EPS growth. The stock increased 3.06% or $0.16 during the last trading session, reaching $5.39. About 164,314 shares traded. ChromaDex Corporation (NASDAQ:CDXC) has declined 38.10% since February 15, 2017 and is downtrending. It has underperformed by 54.80% the S&P500.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company has market cap of $289.97 million. The firm offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside , a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It currently has negative earnings. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications.

More notable recent ChromaDex Corporation (NASDAQ:CDXC) news were published by: which released: “ChromaDex Appoints Mark Friedman as General Counsel and Corporate Secretary” on January 23, 2018, also with their article: “ChromaDex to Present at the 3rd Annual NAD+ Summit” published on January 24, 2018, published: “ICONIQ Capital, LLC Buys ChromaDex Corp, Apple Inc, Apollo Commercial Real …” on February 15, 2018. More interesting news about ChromaDex Corporation (NASDAQ:CDXC) were released by: and their article: “ChromaDex Corporation Reports Preliminary 2017 Results” published on February 12, 2018 as well as‘s news article titled: “Elysium Health, Inc. Challenge of ChromaDex Licensed Patent Denied by Patent …” with publication date: January 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.